menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

ESR1 Mutations in Metastatic Breast Cancer: A Predictor of Poor Prognosis

ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post SurveySkip straight to the post survey if you have already participated in this activity
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    Recent studies have examined the implications of ESR1 mutations in metastatic breast cancer and found that ESR1 mutations predict poor response to subsequent endocrine therapy. These acquired mutations also correlate with aggressive disease and, by extension, worse prognosis. Dive further into these findings from various studies and how they might impact the way we treat patients with metastatic breast cancer with Dr. Pavani Chalasani and Dr. Marcela Mazo Canola, Assistant Professor at UT Health San Antonio’s Mays Cancer Center.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    Recent studies have examined the implications of ESR1 mutations in metastatic breast cancer and found that ESR1 mutations predict poor response to subsequent endocrine therapy. These acquired mutations also correlate with aggressive disease and, by extension, worse prognosis. Dive further into these findings from various studies and how they might impact the way we treat patients with metastatic breast cancer with Dr. Pavani Chalasani and Dr. Marcela Mazo Canola, Assistant Professor at UT Health San Antonio’s Mays Cancer Center.

Facebook Comments

Schedule27 Feb 2024